Literature DB >> 14342251

INHIBITION BY 6-MERCAPTOPURINE OF PURINE PHOSPHORIBOSYLTRANSFERASES FROM EHRLICH ASCITES-TUMOUR CELLS THAT ARE RESISTANT TO THE DRUG.

M R ATKINSON, A W MURRAY.   

Abstract

1. A strain of Ehrlich ascites-tumour cells that showed little inhibition of growth in the presence of 6-mercaptopurine accumulated less than 5% as much 6-thioinosine 5'-phosphate in vivo, in the presence of 6-mercaptopurine, as did the sensitive strain from which it was derived. 2. Specific activities of the phosphoribosyltransferases that convert adenine, guanine, hypoxanthine and 6-mercaptopurine into AMP, GMP, IMP and 6-thioinosine 5'-phosphate were similar in extracts of the resistant and the sensitive cells. 3. As found previously with sensitive cells, 6-mercaptopurine is a competitive inhibitor of guanine phosphoribosyltransferase and hypoxanthine phosphoribosyltransferase from the resistant cells and does not inhibit the adenine phosphoribosyltransferase from these cells. Michaelis constants and inhibitor constants of the purine phosphoribosyltransferases from resistant cells did not differ significantly from those measured with the corresponding enzymes from sensitive cells. 4. Resistance to 6-mercaptopurine in this case is probably not due to qualitative or quantitative changes in these transferases.

Entities:  

Keywords:  ADENINE; ADENINE NUCLEOTIDES; CARCINOMA, EHRLICH TUMOR; CHROMATOGRAPHY; ELECTROPHORESIS; ENZYME INHIBITORS; EXPERIMENTAL LAB STUDY; GLUCOSYLTRANSFERASES; GUANINE; GUANINE NUCLEOTIDES; HYPOXANTHINES; ION EXCHANGE RESINS; KINETICS; MERCAPTOPURINE; METABOLISM; NUCLEOTIDES; PHARMACOLOGY; XANTHINES

Mesh:

Substances:

Year:  1965        PMID: 14342251      PMCID: PMC1206407          DOI: 10.1042/bj0940071

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  3 in total

1.  INHIBITION OF INOSINE 5'-PHOSPHATE DEHYDROGENASE FROM EHRLICH ASCITES-TUMOUR CELLS BY 6-THIONINOSINE 5'-PHOSPHATE.

Authors:  M R ATKINSON; R K MORTON; A W MURRAY
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

2.  Resistance to 6-mercaptopurine. I. Biochemical differences between the Ehrlich ascites carcinoma and a 6-mercaptopurine-resistant subline.

Authors:  A R PATERSON; A HORI
Journal:  Can J Biochem Physiol       Date:  1962-02

3.  INHIBITION OF PRUINE PHOSPHORIBOSYLTRANSFERASES OF EHRLICH ASCITES-TUMOUR CELLS BY 6-MERCAPTOPURINE.

Authors:  M R ATKINSON; A W MURRAY
Journal:  Biochem J       Date:  1965-01       Impact factor: 3.857

  3 in total
  7 in total

1.  Studies on the nature of the regulation by purine nucleotides of adenine phosphoribosyltransferase and of hypoxanthine phosphoribosyltransferase from Ehrlich ascites-tumour cells.

Authors:  A W Murray
Journal:  Biochem J       Date:  1967-04       Impact factor: 3.857

2.  Inhibition of purine phosphoribosyltransferases from Ehrlich ascites-tumour cells by purine nucleotides.

Authors:  A W Murray
Journal:  Biochem J       Date:  1966-09       Impact factor: 3.857

3.  Purine-phosphoribosyltransferase activities in rat and mouse tissues and in Ehrlich ascites-tumour cells.

Authors:  A W Murray
Journal:  Biochem J       Date:  1966-09       Impact factor: 3.857

4.  8-Azaguanine resistance in mammalian cells. I. Hypoxanthine-guanine phosphoribosyltransferase.

Authors:  F D Gillin; D J Roufa; A L Beaudet; C T Caskey
Journal:  Genetics       Date:  1972-10       Impact factor: 4.562

5.  The activities and kinetic properties of purine phosphoribosyltransferases in developing mouse liver.

Authors:  A W Murray
Journal:  Biochem J       Date:  1967-08       Impact factor: 3.857

6.  Hypoxanthine: guanine phosphoribosyltransferase mutants in Saccharomyces cerevisiae.

Authors:  R A Woods; D G Roberts; T Friedman; D Jolly; D Filpula
Journal:  Mol Gen Genet       Date:  1983

7.  Chemical-Chemical Combinations Map Uncharted Interactions in Escherichia coli under Nutrient Stress.

Authors:  Sara S El Zahed; Eric D Brown
Journal:  iScience       Date:  2018-03-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.